Publications by authors named "M P Garssen"
Background And Objectives: To investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study.
Methods: Albuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/μL).
Background: Skeletal injury following a generalized tonic-clonic insult is rare. It is often missed as patients are unable to adequately express their symptoms in the post-ictal state, the apparent lack of a trauma prior to the insult and the low a priori chance. However, in order to ensure adequate treatment, timely diagnosis of these injuries is of great importance.
View Article and Find Full Text PDFArticle Synopsis
- The study looked at a score called mEGOS that helps predict if people with a sickness called Guillain-Barré syndrome (GBS) will be able to walk on their own or not.
- Researchers used information from 1,500 patients from a big study to see if mEGOS worked well for people from different regions and made some improvements to it.
- The updated score showed good results in different areas, but some places had better or worse outcomes than expected, and they found that things like age and how weak someone’s limbs were were important for predicting problems.
In the wake of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, an increasing number of patients with neurological disorders, including Guillain-Barré syndrome (GBS), have been reported following this infection. It remains unclear, however, if these cases are coincidental or not, as most publications were case reports or small regional retrospective cohort studies. The International GBS Outcome Study is an ongoing prospective observational cohort study enrolling patients with GBS within 2 weeks from onset of weakness.
View Article and Find Full Text PDFBackground: Treatment with one standard dose (2 g/kg) of intravenous immunoglobulin is insufficient in a proportion of patients with severe Guillain-Barré syndrome. Worldwide, around 25% of patients severely affected with the syndrome are given a second intravenous immunoglobulin dose (SID), although it has not been proven effective. We aimed to investigate whether a SID is effective in patients with Guillain-Barré syndrome with a predicted poor outcome.
View Article and Find Full Text PDF